School of Medicine, Southeast University, Nanjing, China.
The Second Hospital of Nanjing, Teaching Hospital of Southeast University, Nanjing, China.
Liver Int. 2024 Sep;44(9):2329-2340. doi: 10.1111/liv.16002. Epub 2024 Jun 3.
Porto-sinusoidal vascular disease (PSVD) is an under-recognized and under-diagnosed disease. The purpose of this study was to investigate the clinical features and prognosis of PSVD.
The patients who underwent liver biopsies were analyzed retrospectively. The clinical and pathological data were reviewed and screened according to the latest diagnostic criteria of PSVD.
A total of 234 patients were diagnosed as PSVD, including 103 patients presented with portal hypertension (PH) and 131 patients without PH. At baseline, the alanine aminotransferase (ALT) and γ-glutamyl transpeptidase (GGT) levels were higher in the no-PH group. The liver stiffness increased in the PH group. In histological review, obliterative portal venopathy, sinusoidal dilatation and architectural disturbance were more common in the PH group, while portal tract abnormalities were more widely distributed in the no-PH group. After a median follow-up of 43.6 months, the survival rate of patients with baseline liver decompensation was 76.0%, and that of patients at a liver compensated stage in the PH group was 98.7%. First variceal bleeding occurred in 13.8% of patients with gastric-oesophageal varices. None of the patients in the no-PH group developed portal hypertension during follow-up.
PSVD can manifest as PH or mild liver enzyme abnormalities. There are significant differences in pathological features among patients with different clinical manifestations. Recurrent ascites are the main cause of death in PSVD patients. However, patients without PH have a slow disease progression, with recurrent elevated GGT levels being their main clinical feature.
门-体静脉血管病(PSVD)是一种被低估的疾病。本研究旨在探讨 PSVD 的临床特征和预后。
回顾性分析行肝活检的患者。根据 PSVD 的最新诊断标准,回顾和筛选临床和病理数据。
共诊断出 234 例 PSVD 患者,其中 103 例表现为门脉高压(PH),131 例无 PH。在基线时,无 PH 组的丙氨酸氨基转移酶(ALT)和γ-谷氨酰转肽酶(GGT)水平较高。PH 组的肝硬度增加。在组织学复查中,PH 组更常见闭塞性门静脉病、窦扩张和结构紊乱,而无 PH 组更广泛地存在门脉异常。中位随访 43.6 个月后,基线时存在肝脏失代偿的患者生存率为 76.0%,PH 组处于肝脏代偿期的患者生存率为 98.7%。胃食管静脉曲张患者中有 13.8%发生首次静脉曲张出血。无 PH 组患者在随访期间均未发生门脉高压。
PSVD 可表现为 PH 或轻度肝酶异常。不同临床表现的患者在病理特征上存在显著差异。复发性腹水是 PSVD 患者死亡的主要原因。然而,无 PH 的患者疾病进展缓慢,其主要临床表现为复发性 GGT 水平升高。